(Q44023774)

English

Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

phase II clinical trial

0 references

5

object named as

Hyman B Muss

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Gretchen G Kimmick

1

object named as

Gretchen G Kimmick

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

L. Douglas Case

3

object named as

L Douglas Case

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

Brent J Shelton

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

M Robert Cooper

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

1 April 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

233-243

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

https://scigraph.springernature.com/pub.10.1023/a:1014953407098

0 references

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

21 January 2018

L-phenylalanine mustard (L-PAM) in the management of primary breast cancer:An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

21 January 2018

The CMF program for operable breast cancer with positive axillary nodes:Updated analysis on the disease-free interval, site of relapse and drug tolerance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

21 January 2018

Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

21 January 2018

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

21 January 2018

Vinorelbine (Navelbine): a third-generation vinca alkaloid

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

21 January 2018

Optimizing chemotherapy for patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

21 January 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

21 January 2018

A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer. Eleven year follow-up of a Piedmont Oncology Association trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant therapy of breast cancer: a Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1014953407098

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1014953407098

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44023774&oldid=2105735287"